pharmaphorum

DECEMBER 21, 2021

However, despite the work still left to be done, there are now a growing number of treatments in the pipeline and 2020 proved to be a remarkable year for orphan drug approvals, with the US FDA approving more orphan designated treatments than non-orphan drugs.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Hospitals FDA 98

European Pharmaceutical Review

MARCH 7, 2024

Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization FDA 52

The Checkup by Singlecare

JANUARY 18, 2024

The patent protection for Nexplanon typically prevents other pharmaceutical companies from creating a generic version until the patent expires. in 2027 and other countries in 2025, when a generic version may be approved. Most insurance companies offer health insurance plans that cover Nexplanon and other birth control methods.

Insurance 52

Insurance Insurance Coverage Packaging Pharmaceutical Companies 52

The Checkup by Singlecare

OCTOBER 27, 2023

How to get Vyzulta without insurance Vyzulta is a brand-name prescription eye drop medication that is approved by the Food and Drug Administration (FDA) to reduce eye pressure in people with open-angle glaucoma or high eye pressure. The earliest date that a generic version could be available is in 2025. Is Vyzulta covered by insurance?

Insurance 52

Insurance Pharmaceutical Companies Pharmaceutical Companies FDA 52

pharmaphorum

APRIL 19, 2022

“In a situation where most of the development of treatments in Korea is mostly centred on cancer and metabolic diseases, I noticed that there weren’t any companies that were focusing on sensory diseases.”. Kim says the Dry Eye Disease market is large and growing, with analysts predicting it will hit $6 billion USD by 2025.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication FDA 52

Pharmaceutical Technology

JUNE 19, 2023

Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

The Checkup by Singlecare

MARCH 10, 2025

The medication is available in both brand-name and compounded forms, although the compounded forms are not FDA approved. Compounded semaglutide is made by special compounding pharmacies rather than pharmaceutical companies. Ozempic, Wegovy, and Rybelsus are the only FDA-approved drugs that contain semaglutide.

Compounding 52

Compounding Insurance Insurance Coverage FDA 52

PharmaShots

MAY 23, 2023

Propelled by constant innovatory winds, the Cell and Gene therapy market is anticipated to grow by 20 percent year-over-year through 2025. The company first received the US FDA approval for its gene therapy Zynteglo in Aug 2022 for treating adult and pediatric patients with ß-thalassemia. Total Revenue: $1.9B

FDA 58

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 58

Pharmaceutical Technology

SEPTEMBER 22, 2022

The pharmaceutical company is well on its way to achieving its goals with successful full reimbursements, already confirmed in the United Kingdom ( UK), and Sweden. GlobalData is the parent company of Pharmaceutical Technology. Following this, in 2019, the FDA approved Vazkepa for the reduction of cardiovascular risk.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA Dosage 52

The Checkup by Singlecare

SEPTEMBER 10, 2024

It is approved by the Food and Drug Administration (FDA) to treat plaque psoriasis , psoriatic arthritis , Crohn’s disease , and ulcerative colitis. There have been several biosimilars approved, including Wezlana , Selarsdi, and Pyzchiva, but they are not expected to be available until early 2025. What is a biosimilar?

FDA 52

FDA Vaccines Specialty Pharmacies Pharmaceutical Companies 52

PharmaShots

JUNE 7, 2023

To further expedite the introduction of the biosimilar globally, EirGenix has been in talks with global pharmaceutical companies about licensing the marketing rights to EG1206A 5. Amgen also claims that the US FDA approval decision on the biosimilar candidate could come before its relevant patents expire.

FDA 40

FDA Packaging Pharmaceutical Companies Pharmaceutical Companies 40

The Checkup by Singlecare

FEBRUARY 10, 2025

Food and Drug Administration ( FDA ) in 2014 for Type 2 diabetes. Since then, its FDA -approved uses have expanded, now including kidney disease, heart failure , and Type 2 diabetes. The pharmaceutical company Prasco currently markets a generic version of Farxiga. Is there a generic for Farxiga ?

Dosage 52

Dosage Labelling Hospitals FDA 52

Pharmaceutical Technology

MARCH 22, 2023

According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. From 2025, it will be substituted with a new chapter on functional tests for the complete system.” The demand for injectable drugs is rising.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

The Checkup by Singlecare

JUNE 6, 2024

Farxiga (dapagliflozin) is a brand-name prescription medication that has been approved by the Food & Drug Administration (FDA) for several indications. This law enables Medicare to negotiate directly with pharmaceutical companies, which should ultimately result in lower prescription drug costs for consumers.

Insurance 52

Insurance Hospitals Pharmaceutical Companies Pharmaceutical Companies 52

The Checkup by Singlecare

JUNE 7, 2024

Made by the pharmaceutical company Janssen Biotech, Inc., Wezlana In October 2023 , the Food and Drug Administration (FDA) approved Wezlana , which is an interchangeable biosimilar to Stelara. It works on proteins that affect the immune system, which helps improve symptoms such as inflammation.

Immunization 52

Immunization Dosage Vaccines FDA 52

The Checkup by Singlecare

JUNE 6, 2024

Jardiance is a brand-name drug that was initially approved by the Food and Drug Administration (FDA) to control blood sugar in adults with Type 2 diabetes. The law will allow Medicare to negotiate directly with pharmaceutical companies to improve access to affordable prescription drug costs.

Insurance 52

Insurance Hospitals Vaccines Pharmaceutical Companies 52

European Pharmaceutical Review

JANUARY 23, 2025

M&A dealmaking in 2025 is expected to witness continued growth, however companies need a robust partnering approach to secure future expansion. Another major deal in early 2025 was GSKs announcement that it will acquire the biopharmaceutical company IDRx Inc; an agreement valued potentially up to $1.15 4 References 1.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies FDA 59

Pharma Marketing Network

APRIL 3, 2025

This article dives deep into how patient marketing has changed, whats driving this transformation, and what strategies are leading the way for 2025 and beyond. Navigating Compliance While personalization and interactivity are powerful, they must align with FDA regulations. FAQs What is patient marketing in pharma?

HIPAA 52

HIPAA Communication Packaging Pharmaceutical Companies 52